Multiple sclerosis (MS) is the commonest disabling neurological condition to afflict young adults and therefore has a high social burden. Over several decades, there has been a considerable progress in the understanding of the disease pathogenesis as well as in the clinical management of MS patients. The emphasis in managing MS patients has shifted to multidisciplinary teams working in specialist groups. A review of the literature was conducted using MedLine to identify recent advances in MS. The current consensus is that MS is an autoimmune disease triggered by environmental agents acting in genetically susceptible people. Based on that concept, new methods of immune intervention procedures have been introduced into clinical practice. Licensed first-line disease-modifying therapies reduce the MS attack or relapse rate by a third and delaying short-term disease progression. More effective therapies have emerged; however, these are associated with increased risks. New clinical and pathological insights are making us question the aetiology and pathogenesis of MS. The recognition of pathological heterogeneity has raised the question of whether MS is a single disease entity or a syndrome. Recent evidence suggests that the pathological subtype may predict therapeutic response to specific therapies. A new novel auto-antibody has defined a subset of neuromyelitis optica or Devic's disease as being distinct from MS. This is an attractive concept that is not widely accepted. The observation that MS progresses despite immunosuppressive therapy suggests that MS may be a neurodegenerative disease with overlapping immune activation possibly in response to the release of central nervous system auto-antigens. The development of neuroprotective therapies for MS is required to prevent the devastating effects of long-term disability as a result of progressive disease.
Introduction
Most clinicians have a good working knowledge about what constitutes the clinical entity of multiple sclerosis (MS); however whether or not it represents a distinct clinical entity or a syndrome is a moot point. The identification of pathological heterogeneity 1 has opened up the discussion about whether MS represents more than one disease entity. However, the definitive proof to support the latter concept is lacking. The majority view at present is that MS is a complex disorder, requiring genetically susceptible individuals to be exposed to a set of environmental agents, which subsequently trigger an auto-aggressive immune attack on the myelin sheath and other components of central nervous system (CNS) axons. 2 Current and emerging MS diseasemodifying therapies are based on the above paradigm. Potent antiinflammatory strategies that are effective in suppressing clinical attacks and disease activity on magnetic resonance imaging (MRI) have been disappointing in that they do not necessarily prevent the development of progressive disease. 3 This has led some to suggest that MS may represent a primary neurodegenerative disease. 4 
Epidemiology
MS is the most common inflammatory demyelinating disease of the CNS and is the most common disabling neurological disease to afflict young adults. The mean age of onset is approximately 30 years. Almost 70% of patients manifest symptoms between ages 20 and 40. Disease onset rarely occurs prior to 10 or after 60 years of age. However, patients as young as 3 and as old as 67 years of age have been described. There is clear gender difference with females being more frequently affected than men. The worldwide incidence and prevalence of MS is highly variable with both genetic and geographical factors playing a role. The greatest incidence tends to be at the extremes of latitude in both northern and southern hemispheres. The disease is more common in subjects with Western European ancestry. In particular, Scotland and the Outer Hebrides are the regions with the highest recorded prevalence rates of up to 300 cases per 100 000. In England and Wales, prevalence rates have varied from 74 to 112 per 100 000. In contrast, there are ethnic groups that seem to be resistant to the disease despite inhabiting areas of relatively high prevalence rate such as Maoris in New Zealand, Hutterites and the Natives in Western Canada.
There is no clear explanation for the differences in worldwide distribution of MS. Genetic factors seem to be strongly associated.
The 'Viking theory' suggests that the distribution is strongly linked to the spread of Scandinavian genes, initially by the Vikings and later by a second wave of Scandinavian migration. 5 Interestingly, in a small area on the southern peninsula of China, which the Vikings managed to conquer, the incidence of MS is relatively high compared with the remainder of mainland China. 5 The incidence of MS in first-degree relatives is 20 times higher than in general population. In monozygotic twins the concordance rate has been reported to be as high as 30% compared with rates of less than 5% in dizygotic twins. 6 Genetically unrelated family members living in the same environment are of no higher risk than background population.
Large whole genome screens have identified the HLA region on chromosome 6 as been consistently associated and linked with MS. In Northern Europeans, there is an association and linkage between the presence of the HLA haplotype DR15, DQ6 (commonly referred to as DR2 or Dw2) and MS. 6, 7 DR3 and DR4 genes are associated with MS in some Southern European populations. Subjects presenting with clinically isolated syndromes associated with demyelination (CIS) and who are DR15 positive have a higher likelihood of developing MS. It is difficult to apply this information clinically in individual patients as approximately 35% of the general population are DR15 positive compared with 60 -70% of people with MS. Several other regions of interest have also been identified. Recently, a large international collaborative study provided strong evidence for the involvement of polymorphism of two cytokine receptor genes in the pathogenesis of MS: the interleukin 7 receptor alpha chain gene (IL7RA) on chromosome 5p13 and the interleukin 2 receptor alpha chain gene (IL2RA (¼CD25)) on chromosome 10p15. 7 It is estimated that the C allele of a single nucleotide polymorphism, rs6897932, within the alternative spliced exon 6 of IL7RA is involved in about 30% of MS cases. 7 Several case -control studies using the candidate gene approach have reported genetic polymorphisms that are associated with MS. 8 The majority of these associations, however, are likely to turn out to be false positives. 9 Environmental factors undoubtedly have strong impact on disease distribution and prevalence. This is supported by observations that migration from high-risk to low-risk areas before puberty affords some protection from acquiring MS 10 and numerous outbreaks or clusters of the disease have been described. The viral or infective hypothesis, with a period of latency, has been formulated to explain these observations but all attempts to isolate or passage the disease to animals have failed. Epidemiological data strongly suggests Epstein -Barr virus (EBV) infection is associated with the development of MS. People with symptomatic EBV infection or with higher antibody responses to EBV are at greater risk of developing MS. 11, 12 This observation is not unique to MS and has been noted with other putative autoimmune diseases. It has therefore been proposed that EBV infection increases one's risk of developing autoimmune diseases in general, possibly by immortalizing autoreactive B-cells, which act as professional antigen-presenting cells that drive persistent autoimmunity. 13 EBV may also trigger MS, arguably an organ-specific autoimmune disease, via the process of molecular mimicry. 14 Other infective agents that have been added to the long list of proposed aetiologies, 15 include human herpes virus 6 (HHV-6), MS-related human endogenous retroviruses and Chlamydophila pneumoniae. Another important environmental factor, which has a strong association with the risk of MS is sunlight exposure and vitamin D levels, with a high likelihood of them playing a role in a prenatal period. 16 That hypothesis is based on the close relationship between geographical differences in sunlight exposure and the influence of latitude on MS worldwide prevalence, the direct effects of sunlight exposure on serum vitamin D levels and the immunomodulatory effects of vitamin D on T-cells homeostasis. 17 Other factors, which play a role in the susceptibility to MS include diet, social class, occupation and cigarette smoking.
In conclusion, MS is a complex disease requiring genetic and environmental factors to act at a population level rather than in the familiar microenvironment. 6 
Pathology/pathogenesis
MS is an inflammatory, demyelinating disease of the CNS with variable degrees of axonal loss and gliosis. Traditionally it has been thought that the white matter was the predominant site of involvement. However, many small lesions are also found in the grey matter cortices as well as deep grey matter structures. Macroscopic lesions are most commonly seen in the spinal cord (50%), optic nerves (25%), brainstem/cerebellum (20%) and periventricular white matter. The pathological hallmark of MS is lesions, known as plaques, which are due to focal loss of myelin with relative preservation of axons and astrocytic gliosis. The pathological features of individual lesions vary and depend on location, age and whether or not there has been any regeneration. MS lesions are typically divided into three pathological categories: active (acute), chronic active and chronic inactive. 18 More recently active lesions have been further classified into different pathological subtypes based on the type of inflammatory reaction, the involvement of immunoglobulin and complement, the expression of myelin proteins, the morphology of the plaque edge and the patterns of oligodendrocyte injury.
1 Table 1 summarizes the features and proposed pathological 19 Pathological changes described in new symptomatic lesions include widespread oligodendrocyte apoptosis and microglial activation in myelinated tissue that contained few or no lymphocytes or myelin phagocytes. This was in comparison to older lesions that showed more typical changes with characteristic foci of inflammation. 18 This hypothesis raises a host of probing questions about the presumed pathogenesis and aetiology of MS. Interestingly, another study described that the immunopathological appearance of active demyelinating lesions in established MS was uniform displaying the features of antibody-and complement-mediated myelin phagocytosis as the dominant mechanism of demyelination. 20 This paper suggests, the initial heterogeneity of demyelinating lesions from the earliest phase of MS lesion formation might disappear in the more advanced phases of the disease.
Pathological heterogeneity has potential clinical implications. A recent study from the Mayo clinic suggests that subjects with type II pathology, characterized by IgG deposition and complement activation, are more likely to respond to plasma exchange. 21 Figures 1 and 2 summarizes the current dogma concerning the immunopathogenesis of MS. An important pathological feature in relation to MS is the ongoing axonal loss, which is responsible for irreversible disability and progressive disease. Axonal pathology and transection is demonstrated in both acute and chronic MS lesions. 22 The axonal loss occurs in association with inflammation early in the disease and continues at different levels of intensity throughout the disease course. Particular interest has focused on the cortical pathology associated with MS. Post-mortem studies revealed that extensive cortical demyelination is typically Fig. 1 The proposed pathogenesis of MS. Genetic susceptibility and exposure to an environmental agent in childhood induces auto-reactive T-cells. After a latent period a systemic trigger activates these auto-reactive T-cells, which cross the blood-brain barrier selectively and on re-exposure to their auto-antigen initiate a cell-mediated inflammatory reaction (Fig. 2) . This inflammation results in demyelination and axonal loss. Sequestered CNS antigens, which are released as a result of tissue damage, initiate further episodes of autoimmune-induced inflammation. Focal inflammation causes axonal toxicity, demyelination and conduction block. Whether or not a lesion results in clinical symptoms and/or signs depends on the anatomical site and size of the lesion as well as the integrity of the neuronal pathway involved. Axonal plasticity, i.e. the synthesis of sodium channels in demyelinated nerve segments or remyelination in conjunction with grey matter plasticity results in functional recovery. Persistent demyelination leads to a gradual loss of axons, resulting in the development of progressive neurological impairment. present in patients with progressive disease. Cortical demyelination and injury of the NAWM, reflected by diffuse axonal injury with profound microglia activation, occurred on the background of a global inflammatory response in the whole brain and meninges. 23 Three main types of cortical lesions have been described: cortico-subcortical (leukocortical) lesions, affecting cortex and adjacent white matter, small, purely intracortical lesions and subpial lesions directly abutting on the subarachnoid space. 24, 25 The pathology of grey matter lesions differs from that of white matter lesions with less inflammatory features as expressed by less macrophage and lymphocyte infiltration suggesting the apparent paucity of an adaptive immune response in the demyelinated cortical parenchyma. This however is accompanied by significant axonal transections and neuronal loss. Interestingly, quite a different picture is described in the sulcal meninges where follicle-like structures T-cells are then activated by antigen-presenting cells, proliferate and produce a range of pro-inflammatory cytokines. These cytokines activate local microglia, astrocytes and endothelial cells, which in turn produce pro-inflammatory cytokines, such as IL-1 and TNF-a. These up-regulate the expression of adhesion molecules on endothelium and in combination with chemokines (chemoattractants cytokines) recruit other inflammatory cells into the lesion. Cytotoxic mediators, including reactive oxygen and nitrogen species, proteases, eicosanoids, granzyme, perforin and excitotoxic factors, which in combination with auto-antibodies, complement activation and the effects of pro-inflammatory cytokines cause oligodendrocyte cell death and demyelination. These factors also cause axonal damage. Immunomodulatory cytokines, e.g. IL4, IL10 and TGFb and growth or trophic factors, e.g. brain-derived neurotrophic factor, produced by T-cells subsequently downregulate inflammation and promote the proliferation and survival of the oligodendrocyte.
harbouring B-cells as well as follicular dendritic cells are found in a subset of secondary progressive (SP) MS patients. The presence of these follicle-like structures is associated with more frequent and more extensive subpial cortical lesions. Furthermore, these lesions were associated with more extensive damage to cortical neuronal structures and linked to disability and early death. Further study revealed that follicle-like structures were positive for Epstein -Barr virus (EBV) RNA and protein, suggesting an aberrant B-cell-dominated immune response, probably in relation to chronic EBV infection. 26 This observation has not been replicated 27 but has rejuvenated interest in the close association between EBV and MS. 28 Clinical presentation, classification and natural history Classification Table 2 and Figure 3 represent a widely used contemporary clinically based classification of MS. 29 Approximately 85% of subjects with MS have relapse-onset disease in which the disease manifests with an index attack from which the majority of subjects make a full or partial recovery. At this stage they are referred to as having a clinically isolated syndrome compatible with demyelination. A diagnosis of MS can be made after one clinical attack, provided the diagnostic criteria for dissemination in time and space are fulfilled using MRI and/or electrophysiological techniques (Tables 3 -5) . 30 One can now predict with reasonable certainty which patients presenting with a CIS will go onto develop MS. After 14 years of follow-up, clinically definite MS will develop in greater than 80% of subjects with CIS and an abnormal MRI at presentation compared with less than 20% of subjects with a normal MRI. 
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Disease course
The majority of patients with relapse-onset MS, given sufficient time, will go onto develop SP disease. SP MS is represented by two clinical subtypes: 1 relapsing-SP disease in which progression results from a failure to recover from relapses and 2 non-relapsing-SP disease in which disability is acquired relentlessly in the absence of superimposed relapses. Defining these subtypes clinically is not straightforward but the distinction is important therapeutically. Patients with relapsing-SP disease are more likely to have evidence of disease activity on MRI, in the form of focal gadolinium (Gd) enhancement, and are more likely to respond, albeit it modestly, to immunomodulatory therapies. A small subset of subjects compromising approximately 10-15% of the MS population has primary progressive (PP) MS, with progressive disease from the outset. 32 Interestingly a small minority of these people with PPMS will go onto have relapses and are referred to as progressive relapsing MS.
The development of neurological impairment and disability has facilitated long-term MS natural history studies. The most popular and most commonly used scale is the expanded disability status scale. 33 In a study by Runmarker and Anderson 34 80% of patients developed SP disease after 25 years of the follow-up; 15% had died and 65% of subjects required a walking aid. It needs to be emphasized that MS is an unpredictable disease. Good prognostic signs include, female sex, a younger age of onset, an initial presentation of either optic neuritis or sensory symptoms, full recovery from the first attack, a long period of time between the first and second attacks and a low baseline lesion load on MRI. 35 Although, the concept of benign MS has been widely championed, 36 it is not possible to use these prognostic factors to predict who will have benign MS. Firstly, the proportion of people with benign MS, i.e. those with no or minimal disability after a defined period of time, reduces with time. At 15 years after the onset of MS approximately 30% of patients have benign MS; this figure drops to 15% at 25 years and 5% after 30 years disease duration. 37 These figures probably underestimate the true proportion of benign disease as they are based on the long-term follow-up of If the criteria indicated are fulfilled, the diagnosis is MS; if the criteria are not completely met, the diagnosis is 'possible MS'; if the criteria are fully explored and not met the diagnosis is 'not MS'. No additional tests are required: however, if tests (MRI, CSF) are undertaken and are NEGATIVE, extreme caution needs to be taken before making a diagnosis of MS. Alternative diagnoses must be considered. There must be no better explanation for the clinical picture. MRI demonstration of space dissemination must fulfil criteria in Table 4 . Positive CSF determined by OCBs detected by established methods (preferably isoelectric focusing) different from any such bands in serum or by a raised IgG index. MRI demonstration of time dissemination must fulfill criteria in Table 5 . Abnormal visual evoked potential of the type seen in MS (delay with a well-preserved wave form).
Multiple sclerosis
British Medical Bulletin 2010;95 predominantly hospital-based cohort of subjects; 35 as hospital-based subjects tend to have worse disease. A recent community-based natural history study from Olmsted County in Rochester indicates that on average the course of MS is more benign. 38 This latter study would support the Danish post-mortem data that has indicated that approximately a fifth of the general population with pathological evidence of MS at post-mortem were undiagnosed in life; 39 this would indicate that these subjects had either benign or had asymptomatic disease. We would not recommend using the term 'benign MS', unless it is strictly defined, as it is misleading. Malignant MS is a term that is also frequently used. This typically refers to subjects who have frequent disabling attacks with poor recovery and as a result develop a rapidly progressive course, with severe disability or death occurring within a period of less than 2 years. The mechanisms determining these extremes are not defined but may relate to genetic factors; for example apolipoprotein E4 which confers susceptibility to Alzheimer's disease, and is associated with unfavorable clinical outcomes in head trauma and cerebrovascular disease, has also been linked to a poorer clinical outcome in MS. 40 
Disease modifiers
Overall pregnancy does not have a deleterious effect on the course of MS. In fact nulliparous women with MS have a poorer long-term outcome than multiparous women. 41 The relapse rate decreases 43 There is a consistent but weak association between stressful life events and subsequent exacerbation in MS. 44 Surprisingly, it remains uncertain what impact relapses have on the development of progressive disease and whether elimination of relapses early in the course of the disease will prevent secondary progression. 4 Survival in MS is only marginally shortened by 5-7 years compared with general population in western countries. Unfortunately, suicide is a significant factor in the reduction in survival rate. 45 
Ms variants
Neuromyelitis optica (Devic's disease) Neuromyelitis optica (NMO) or Devic's disease is really a syndrome with several potential causes-one of which is MS. It is relatively rare in Western Europe and is more common in Africa and Asia. The optico-spinal form of MS that occurs in Japan is almost certainly the same entity as NMO. 30 NMO is a chronic, inflammatory, demyelinating disease of the CNS, which resembles MS. It is characterized by attacks of acute optic neuritis, which is often bilateral. Within days to months, the optic neuritis is followed by transverse myelitis. In approximately a fifth of cases, the myelitis precedes the optic neuritis. The transverse myelitis tends to be complete and is typically associated with extensive signal change in the cord extending over many segments with swelling of the cord. The optic neuritis in Devic's is usually retrobulbar. Recovery from attacks of Devic's disease tends to be poorer than that from MS. Relapses are usually less frequent than is typical in MS. The brain MRI is normal and there the disease is not associated with intrathecal synthesis of oligoclonal IgG. Recently, NMO has been associated with a characteristic auto-antibody, detectable in the serum of patients with neuromyelitis optica, which differentiates it from typical MS. 30 Neuromyelitis optica immunoglobulin G (NMO-IgG) binds to aquaporin-4, which is the main channel that regulates water homoeostasis in the central nervous system. 46 Pathologically there is extensive immunoglobulin deposition and complement activation. NMO responds acutely to plasma exchange. 47 Anecdotal reports suggest that long-term Azathioprine therapy reduces recurrent attacks of NMO. Only recently, it has been suggested that rituximab, a monoclonal antibody directed against B-cells, could be efficacious in suppressing immune response in NMO patients, but this requires further studies. 48 
Marburg's variant
The Marburg's variant of MS is a very aggressive form of MS where the disease advances very quickly and relentlessly. It is associated with severe axonal loss and leads to rapid disability and death. It is also referred to as acute or fulminant MS.
Balo's concentric sclerosis
Balo's concentric sclerosis is a MS variant characterized pathologically by concentric rings of alternating demyelinated and undemyelinated tissue, which are visible macroscopically. These rings can be seen on MRI. Balo's concentric sclerosis is a rare and a relatively acute condition. Attacks proceed rapidly over weeks or months, typically without remission, in a manner similar to Marburg's variant, usually resulting in death or severe disability. More recently, however, an increasing number of cases have been reported where the disease has been self-limiting with some remission. Balo's concentric sclerosis appears to be more common in Asian populations. Balo's concentric sclerosis often presents with greater cortical dysfunction than typical MS, with aphasia, cognitive or behavioural dysfunction and seizures. Microscopically acute lesions of Balo's concentric sclerosis are associated with type II pathology with prominent IgG deposition and complement activation.
Schilder's disease
Schilder's disease is an inflammatory demyelinating disease that affects children. The clinical signs of Schilder's disease are similar to those of MS but typically progress rapidly over the first 2 years. No specific MR pattern is described that differs from anything that may be seen in MS; however, the white matter lesions tend to be large, extensive and confluent. Most clinicians accept Schilder's disease as being part of the MS spectrum.
Diagnosis and clinical follow-up
The original Schumacher diagnostic criteria required evidence on physical examination alone for dissemination in time and space. These were subsequently modified by Poser et al. 49 to include evoked potentials and CSF examination. The most recent McDonald criteria incorporate MRI findings for determining whether lesions on brain MRI are abnormal and whether these abnormalities satisfy the criteria for dissemination in time and space. The McDonald criteria simplify the diagnostic outcome to being 'MS', 'possible MS' or 'not MS'. 50 As these criteria now allow a diagnosis of MS to be made in subjects presenting with a CIS they have important practical implications for the use of MRI in clinical practice.
The McDonald criteria have been criticized for being too reliant on paraclinical evidence in particular MRI changes. Some of the controversies were addressed in the revised version of the criteria published in 2005. 51 One has to remember that a large number of diseases can mimic the white matter changes that are seen in MS (Table 6 ). It is therefore important to exclude these disorders with appropriate clinical and laboratory investigations before making a diagnosis of MS.
Evoked potentials and central motor conduction times are often abnormal in MS. They are useful diagnostically as they are able to detect clinically silent foci of demyelination in specific sensory and motor pathways. They are also useful if they show clear evidence of CSF examination helps to exclude other inflammatory conditions affecting the CNS, which mimic MS, for example neurosarcoidosis. The detection of intrathecal oligoclonal IgG bands (OCBs) in the CSF is an invariable feature of MS, being found in up to 98% of patients with clinically definite MS. With the increasing availability of MRI lumbar puncture and CSF analysis is being done less frequently. CSF analysis is important, but not essential, for the diagnosis of PPMS. 52 However, if CSF analysis does not show local synthesis of OCBs it should make one reassess the case or at least consider alternative diagnoses. The negative predictive value of not finding local synthesis of OCBs is invaluable in helping one not make a diagnosis of MS. This is not an uncommon problem as people with somatization disorders often present with nonspecific neurological symptoms suggestive of MS.
MRI technology facilitates detection of brain lesions associated with MS and the use of MRI to demonstrate dissemination of disease in time and space is central to the new diagnostic criteria. 50 The standard MRI sequences include conventional T2-weighted, Gd-enhanced and non-enhanced T1-weighted, as well as proton-density-weighted images. Unfortunately, the correlation between pathological changes on standard MRI sequences and clinical outcome in MS is relatively poor over the short-to medium term 53 and therefore cannot be used for monitoring disease activity in individual patients. Newer MR techniques such as magnetization transfer imaging; MR spectroscopy and progressive cerebral atrophy appear very promising as potential surrogate markers in clinical studies.
Despite intense study there are currently no immunological or biochemical markers that are suitable for monitoring disease activity in patients with MS. 54 
Therapy
Disease-modifying agents
Currently, interferon beta (IFNb), glatiramer acetate (GA) and natalizumab are the only three classes of compounds that have been licensed as disease-modifying therapies for MS in the UK. Mitoxantrone (Novantrone w ) has also been licensed for subjects with active MS in the US and some European countries. In relapsing MS, IFNb and GA reduce the relapse rate by approximately a third and severe attacks, i.e. those requiring hospital admission and/or intravenous steroids, by a approximately a half. In addition, IFNb reduces the rate of disease progression by approximately 12 months in the short term. These figures represent averages and hide the observation that some patients do better than others. Therefore, individuals with MS could hope for a better outcome that these often quoted figures. The down-side however is that some subjects fail to respond to these therapies. Currently it is not possible to predict who will respond to therapy. In the UK, the National Institute of Clinical Excellence has ruled that IFNb and GA are not cost-effective and therefore should not be made available through the NHS. 55 In response to this the Department of Health (DoH) in partnership with the pharmaceutical industry have launched the DoH risk sharing scheme, 56 which allows patients eligible for the therapy according to the Association of British Neurologists' (ABN) guidelines to receive these therapies. 57 This is scheme is designed to collect long-term data on disability to assess the cost-effectiveness of these therapies over at least 10 years. 56 The decision of which preparation to choose for any particular individual with MS is a complex one and depends on many individual factors in addition to data on relative efficacy and side-effects profiles of the individual compounds. Involving the patient in the decision process improves concordance. To help this process a web-based decision aid to help people with MS come to a decision regarding therapy has been developed. 58 
Interferon beta
There are three commercial preparations of IFNb, one IFNb-1b (Betaferon w and Extavia w ) preparation and two IFNb-1a (Avonex w , Rebif w ) preparations. All three preparations are licensed for use in RR MS, 59 but only IFNb-1b (Betaferon w ) has been licensed for use in ambulatory patients with SP disease. The most common systemic side effects include flu-like symptoms, which usually subside within 2 to 3 months of initiating therapy. These symptoms can be minimized by a gradual dose escalation, administering IFNb at night and by the prophylactic use of non-steroidal anti-inflammatory agents. IFNb also causes abnormalities in liver function tests and a mild lymphopaenia, which necessitates regular blood monitoring. Subcutaneous injection of IFNb typically causes redness, tenderness, swelling and rarely skin necrosis at the injection site. Cooling the skin with an ice cube prior to injection and rotating the site of the injection helps limit the local side effects. Although there have numerous reports of head-to-head studies comparing the clinical efficacy of the available preparations only two studies can be classified as having produced class I evidence. 59 Both these studies showed that more frequently administered IFNb preparations (IFNb-1b, Betaferon w ; IFNb-1a, Rebif w ) were superior to the once weekly administration of IFNb-1a (Avonex w ). 60, 61 However, these studies only compared the efficacy of these preparations over a Multiple sclerosis relatively short period of time (12-24 months) in a window were the effects of neutralizing anti-IFNb antibodies (NAbs) would not be expected to have an effect.
The three preparations have differing immunogenicities that relate to the molecular biology of the product, the manufacturing process and the therapeutic regimen. 62 NAbs develop in less than 5% of subjects treated with weekly intramuscular IFNb-1a (Avonex w ) compared with 12 -35% of subjects treated with subcutaneous IFNb-1b (Betaferon w ) and IFNb-1a (Rebif w ). The development of NAbs are delayed and hence their effect on efficacy is delayed and only seen after 18 -24 months of therapy. 62 NAbs reduce efficacy on both relapse rate and MRI outcomes and probably on disease progression as well. 62 Up to 60% of patients who develop neutralizing antibodies, particularly patients receiving interferon beta-1b and those with low titre, lose their antibody reactivity on extended follow-up.
Glatiramer acetate
GA, previously known as copolymer-1, is a mixture of synthetic polypeptides composed of glutamic acid, lysine, alanine and tyrosine. The peptide mix is believed to mimic peptide fragments of myelin basic protein, a putative auto-antigen in MS, which blocks T-cell activation or possible acts as an altered peptide ligand. In a trial of 251 patients with early RR MS, daily subcutaneous administration of GA reduced the relapse rate over a 2-year period by 29% 63 and also has a positive effect on MRI markers of disease activity. 64 GA was not shown to delay the development of disability. 64 GA is associated with mild and transient skin reactions and rarely a systemic reaction with tightness of the chess and facial flushing. The latter is believed to be an allergic type reaction due to histamine release. GA is not associated with liver function abnormalities or alteration in blood counts. Recently the longterm administration of GA has been associated with the development of focal lipoatrophy at the site of injection. GA is not licensed for use in patients with SP MS. A large double-blind, placebo-controlled, multi-centre trial of GA in PPMS was stopped after a planned interim analysis showed it not to be effective. 65 Two head-to-head studies comparing GA with IFNbeta-1a and IFNbeta-1b did not demonstrate any difference in efficacy between the two classes of drugs.
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Mitoxantrone
Mitoxantrone is a cytotoxic with immunosuppressive properties. It inhibits T-cell activation, T-and B-cell proliferation, antibody production and macrophage activation. In a study to evaluate the efficiency of Mitoxantrone in highly active MS, subjects were randomized to receive either Mitoxantrone (20 mg intravenously (IV) monthly) and methylprednisolone (1 g IV monthly) or methylprednisolone (1 g IV monthly) alone over 6 months. 68 In the steroid alone group five patients dropped out due to severe exacerbation. MRI analysis showed significantly more patients with no new enhancing lesions in the Mitoxantrone group compared with the steroid alone group (90% v 31%, P , 0.001). In a subsequent European multi-centre study (MIMS study) 194 patients with active RR MS with incomplete recovery or SP MS were randomized to receive Mitoxantrone at a dose of 5 or 12 mg/m 2 or placebo administered intravenously once every 3 months for 24 months. 69 Mitoxantrone significantly reduced progression of disability, annualized relapse rate, number of new Gd-enhancing brain MRI lesions and progression of total T2-weighted brain MRI lesion area. Clinical benefits were sustained in patients who received treatment for 2 years and maintained at follow-up at 36 months. Mitoxantrone, as administered in these studies is generally well tolerated, with no significant cardiac dysfunction. A worrying but rare side effect is treatment-related leukaemia. Mitoxantrone should therefore only be used in patients with very active RR or relapsing-SP MS, preferably with demonstrable Gd enhancement on MRI. These subjects would have typically failed the above first-line therapies.
Natalizumab and other monoclonal antibodies
Natalizumab was the first mAb to be approved in Europe and the USA for the treatment of RR MS. Natalizumab is a recombinant, humanized mAb against the a4 chain of a4b1 integrin that also binds to a4b7 integrin; the a4b1 integrin very-late-antigen-4 (VLA4) is expressed on all leucocytes except neutrophils. Natalizumab is an antagonist of VLA4 that blocks it from binding to vascular cell adhesion molecule (VCAM), which is upregulated on the endothelium during inflammation. In the phase III AFFIRM trial, monotherapy with natalizumab decreased annual relapse rate by 68%, the rate of disability progression by 42%, the number of brain T2-weighted MRI lesions by 83% and the number of brain Gd-enhancing MRI lesions by 92%, compared with placebo. 70 In the phase III SENTINEL trial, natalizumab and intramuscular interferon beta-1a improved clinical outcome compared with intramuscular interferon beta-1a alone. 71 The major adverse effect associated with the therapy is progressive multifocal leukoencephalopathy. The report of two cases in patients treated with natalizumab in combination with interferon beta-1a led to temporary suspension of the drug. The further assessment of the treatment effects helped to reapprove natalizumab by the US Food and Drug Administration as a second-line monotherapy for patients with relapsing forms of MS who have not responded to other immunomodulating therapies. Since the re-launch of natalizumab there have been 43 cases of progressive multifocal leukoencephalopathy (PML) reported with over 60 000 natalizumab-treated patients worldwide (Biogen-Idec safety update March 2010).
Other monoclonal antibodies: daclizumab, 72 anti-CD20 (rituximab, ocrelizumab) 73 and alemtuzumab 74 are candidate drugs, currently being tested in phase III clinical trials.
Unlicensed therapies
Azathioprine, methotrexate, pulsed cyclophosphamide and high-dose intravenous immunoglobulin are a few of the agents that are commonly used off-license as disease-modifying therapies in MS. As class I data in support of their use is lacking their use is not recommended.
Oral drugs
Long-term efficacy of currently available parenterally administered therapies might be altered and weakened by several factors including their immunogenicity, and patients' limited adherence to the prescribed treatment schedule. Orally administered drugs may prove to be more acceptable and convenient to patients, and this may lead to enhanced patient adherence to medication in the long-term perspective. Several oral therapies are currently in Phase III development for use in MS: BG-12, laquinimod and teriflunomide. 75 Only recently, the results of two Phase III trials with cladribine tablets 76 and fingolimod 77 have been published, demonstrating impressive efficacy in reducing relapse rates, the risk of disability progression and MRI measures of disease activity for both compounds with relatively infrequent but potentially serious side effects.
Potential future therapies in trial
It is very reassuring that an increasing number of agents are currently undergoing clinical testing in patients with MS. A list and brief description of the rationale behind some of these agents is presented on the National MS Society website.
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Symptomatic therapies
Despite the intense focus on disease-modifying therapies, symptomatic and physical therapies remain the cornerstone in the long-term management of MS. Symptomatic therapies have the potential to significantly improve the quality of life of people suffering from the ravages of the disease. As MS has the potential to impact on wide number of functional neurological systems it is advisable to use a check list to enquire about specific symptoms and whether or not they are disabling. There are no licensed therapies for MS-related fatigues; both Amantadine and modafinal are widely prescribed off-license. Stimulants should be used with caution: there is little evidence to support their efficacy and they commonly cause anxiety and insomnia. Pemoline is not available in the UK. Although efficacious use of 4-aminopyridine, a centrally acting K þ -channel blocker, is limited by side effects. Cooling suits may be helpful in patients with profound heat sensitivity.
Continued
Multiple sclerosis
It is important to ascertain whether or not these symptoms and disability are a handicap, i.e. impacting on activities of daily living and on social and/or occupational functioning. It is desirable to manage Acute bulbar dysfunction occurring as a result of a brainstem relapse should be treated expectantly. Decisions to perform tracheostomy and percutaneous gastrostomy for bulbar dysfunction should be made on the merits of the individual case.
symptoms early rather than when a crisis arises. Table 7 is a brief summary of the major symptomatic therapies. The effective management of a chronic disease like MS requires a multidisciplinary approach. When appropriate intensive rehabilitation improves disability, handicap, emotional well-being and health-related quality of life but has little or no effect on neurological impairment.
Currently there is little evidence to support or refute any of the claims made concerning the beneficial effects of various diets or dietary supplements in MS.
Conclusion
In conclusion, MS is a complex and multifaceted disease. New clinical and pathological insights are making us question the aetiology and pathogenesis of MS. New diagnostic criteria and the introduction of disease-modifying therapies have changed clinical practice. The emphasis in managing MS patients has shifted to multidisciplinary teams working in specialist groups. Emerging therapies that appear to be more efficacious than currently licensed disease-modifying therapies gives one hope that this disease can be conquered.
